Zenaxis (CEO Son Mi-kyung) and the Foundation for Medical Innovation (FMI), a foundation specializing in supporting researchers and entrepreneurs in the biotechnology field, announced on the 23rd that they have signed a strategic memorandum of understanding (MOU) to jointly support the discovery and growth of bio and healthcare startups.
This agreement focuses on establishing a collaborative structure centered on investment and nurturing, enabling technology-based startups to move beyond the research phase and advance to commercialization and scale-up. The two organizations plan to gradually pursue practical acceleration collaboration, identifying promising startups early and connecting them with the necessary resources for each stage of growth.
Biotech startups often struggle with growth stagnation due to lack of funding, commercialization, and networking after research, despite their strong technological capabilities. This agreement addresses these limitations through a collaborative model that organically links research infrastructure, initial investment and incubation, and commercialization.
The Future Medical Research Foundation has been fostering an environment where research results can lead to startups by leveraging its network of medical and bio experts and its startup infrastructure. To achieve this, it provides researcher support, commercialization training, startup incubation, and venture investment. Recently, it has expanded its LP investment to support early-stage biotech startups.
As a TIPS operator, Zenaxis discovers early-stage startups in the deep tech, bio, and healthcare sectors, connects them with investments, operates acceleration programs, and supports their subsequent growth. Based on its understanding of technology, Zenaxis possesses strengths in advancing business models, market entry strategies, and connecting them with follow-up investments.
Through this agreement, the two organizations plan to establish a cooperative structure that continuously connects elements of startup growth stages, including joint discovery of promising bio startups, early-stage screening, fund raising and investment linkage, full-cycle R&D support including research equipment utilization, technology transfer, patents, and demonstration testing, business model advancement and growth strategy establishment, and support for global expansion and subsequent growth stages.
Zenaxis stated, “This agreement goes beyond discovering and investing in startups, but rather involves collaboration to create growth potential from a scale-up perspective,” adding, “We will continue to provide practical support so that bio startups can grow into sustainable companies based on their technological competitiveness.”
- See more related articles
You must be logged in to post a comment.